These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 10729234)

  • 21. Immunostimulatory oligodeoxynucleotides are potent enhancers of protective immunity in mice immunized with recombinant ORFF leishmanial antigen.
    Tewary P; Sukumaran B; Saxena S; Madhubala R
    Vaccine; 2004 Aug; 22(23-24):3053-60. PubMed ID: 15297055
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interleukin-15 enhance DNA vaccine elicited mucosal and systemic immunity against foot and mouth disease virus.
    Wang X; Zhang X; Kang Y; Jin H; Du X; Zhao G; Yu Y; Li J; Su B; Huang C; Wang B
    Vaccine; 2008 Sep; 26(40):5135-44. PubMed ID: 18462848
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The potential of CpG oligodeoxynucleotides as mucosal adjuvants.
    McCluskie MJ; Weeratna RD; Payette PJ; Davis HL
    Crit Rev Immunol; 2001; 21(1-3):103-20. PubMed ID: 11642598
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Local and systemic B cell and Th1 responses induced following ocular mucosal delivery of multiple epitopes of herpes simplex virus type 1 glycoprotein D together with cytosine-phosphate-guanine adjuvant.
    Nesburn AB; Ramos TV; Zhu X; Asgarzadeh H; Nguyen V; BenMohamed L
    Vaccine; 2005 Jan; 23(7):873-83. PubMed ID: 15603887
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mucosal and systemic immune responses by intranasal immunization using archaeal lipid-adjuvanted vaccines.
    Patel GB; Zhou H; Ponce A; Chen W
    Vaccine; 2007 Dec; 25(51):8622-36. PubMed ID: 17959279
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ADP-ribosylating bacterial enzymes for the targeted control of mucosal tolerance and immunity.
    Lycke N
    Ann N Y Acad Sci; 2004 Dec; 1029():193-208. PubMed ID: 15681758
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In defense of mucosal surfaces. Development of novel vaccines for IgA responses protective at the portals of entry of microbial pathogens.
    McGhee JR; Mestecky J
    Infect Dis Clin North Am; 1990 Jun; 4(2):315-41. PubMed ID: 2189002
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human immunodeficiency virus (HIV)-specific immune responses are generated with the simultaneous vaccination of a gp120-depleted, whole-killed HIV-1 immunogen with cytosine-phosphorothioate-guanine dinucleotide immunostimulatory sequences of DNA.
    Moss RB; Diveley J; Jensen FC; Gouveia E; Carlo DJ
    J Hum Virol; 2001; 4(1):39-43. PubMed ID: 11213932
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Orally administered OVA/CpG-ODN induces specific mucosal and systemic immune response in young and aged mice.
    Alignani D; Maletto B; Liscovsky M; Rópolo A; Morón G; Pistoresi-Palencia MC
    J Leukoc Biol; 2005 Jun; 77(6):898-905. PubMed ID: 15758079
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antigen-immunostimulatory oligonucleotide conjugates: mechanisms and applications.
    Datta SK; Cho HJ; Takabayashi K; Horner AA; Raz E
    Immunol Rev; 2004 Jun; 199():217-26. PubMed ID: 15233737
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Suppression of allergic response by CpG motif oligodeoxynucleotide-house-dust mite conjugate in animal model of allergic rhinitis.
    Mo JH; Park SW; Rhee CS; Takabayashi K; Lee SS; Quan SH; Kim IS; Min IY; Raz E; Lee CH
    Am J Rhinol; 2006; 20(2):212-8. PubMed ID: 16686392
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adjuvants modulating mucosal immune responses or directing systemic responses towards the mucosa.
    Cox E; Verdonck F; Vanrompay D; Goddeeris B
    Vet Res; 2006; 37(3):511-39. PubMed ID: 16611561
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intranasal immunization with tetanus toxoid and CNF1 as a new mucosal adjuvant protects BALB/c mice against lethal challenge.
    Munro P; Flatau G; Lemichez E
    Vaccine; 2007 Dec; 25(52):8702-6. PubMed ID: 18035455
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune response by nasal delivery of hepatitis B surface antigen and codelivery of a CpG ODN in alginate coated chitosan nanoparticles.
    Borges O; Cordeiro-da-Silva A; Tavares J; Santarém N; de Sousa A; Borchard G; Junginger HE
    Eur J Pharm Biopharm; 2008 Jun; 69(2):405-16. PubMed ID: 18364251
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CpG DNA as mucosal adjuvant.
    McCluskie MJ; Davis HL
    Vaccine; 1999 Sep; 18(3-4):231-7. PubMed ID: 10506647
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mucosal vaccines: a paradigm shift in the development of mucosal adjuvants and delivery vehicles.
    Srivastava A; Gowda DV; Madhunapantula SV; Shinde CG; Iyer M
    APMIS; 2015 Apr; 123(4):275-88. PubMed ID: 25630573
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Mucosal immunity].
    van der Heijden PJ; Bianchi AT
    Tijdschr Diergeneeskd; 1990 Nov; 115(22):1058-64. PubMed ID: 2256097
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunostimulatory sequence oligodeoxynucleotide-based vaccination and immunomodulation: two unique but complementary strategies for the treatment of allergic diseases.
    Horner AA; Raz E
    J Allergy Clin Immunol; 2002 Nov; 110(5):706-12. PubMed ID: 12417878
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New advances in mucosal vaccination.
    Ranasinghe C
    Immunol Lett; 2014 Oct; 161(2):204-6. PubMed ID: 24462961
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.